With a $1.36 billion buyout, Merck is bolstering its oncology program with the acquisition of Biotech Bay-based Imago Biosciences, a company focused on chronic bone marrow cancers.
https://www.pharmalive.com/wp-content/uploads/2021/10/Merck-Sees-Positive-Signals-for-HIV-Drug-in-Phase-III-BioSpace-10-25-21.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2022-11-21 11:26:562022-11-21 11:26:56Merck acquires Imago and its LSD1 inhibitors in $1.3B deal
